AtriCure, Inc.

Fundamentals6.0
Price Action7.0
News Sentiment6.0
AI Rating
7.0

Key Drivers

  • Strong Liquidity
  • Fragile Profitability
  • Rich Valuation

AI
AI Summary

7.0

ATRC has shifted from a pure growth story to a “prove the inflection” trade, where the real upside now depends on confirming repeatable profitability and free cash flow in the next earnings cycle, because the stock's sharp breakout has already priced in much of the improvement and leaves little room for another disappointment.

Profitability
ExecutionRisk
MedTech‍

Price Chart

Loading chart...

Financial Metrics

-
Revenue (TTM)
-
Net Income (TTM)
-
EPS (Q)
-
MCAP

Deep Analysis

Research tool. Not personalized advice.

Fundamental Analysis

6.0

Key Financial Insights:

  • Strong Liquidity
  • Fragile Profitability
  • Rich Valuation

ATRC has a strong balance sheet and high gross margins, but inconsistent earnings, weakening recent cash flow, and a rich valuation make the stock a high-risk hold unless profitability improves.

liquidity
valuation

Price Behavior

7.0
Research tool. Not personalized advice. Technical analysis is for informational purposes only.

Key Price Behavior Insights:

  • Breakout Held
  • Higher Highs
  • Volatility Rising

ATRC is in a strong last-month uptrend with a confirmed breakout above $30, but the move looks extended, so holding above the $30 area is key to avoid a pullback.

bullish
volatile
Support Level: $30.18; stronger support at $27.98-$28.13
Resistance Level: $31.79

Sharp jump from $27.98 on 2026-06-30 to $31.79 two sessions later signals short-term volatility risk

Sentiment & News

6.0

Key News Insights:

  • Conference visibility
  • Options activity
  • Earnings caution

AtriCure drew heightened investor attention in June/July 2026 through conference visibility, unusual options activity, and a volume-led stock pop, but cautious earnings revisions and the upcoming Q2 report temper near-term upside.

ATRC
Healthcare

The news flow is supportive of trading interest but remains cautiously neutral until second-quarter results confirm fundamentals